Suchergebnisse - "Morisset, Ludivine"

PubPharm (18)

1

Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers

enthalten in: Cancer research | 2024

von Soosainathan, A. | Iravani, M. | El-Botty, R. | +12

2

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers

enthalten in: Nature communications | 2023

von Ter Brugge, P. | Moser, S. | Bièche, I. | +30

3

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant

enthalten in: Breast cancer research : BCR | 2021

von Jacquemetton, J. | Kassem, L. | Poulard, C. | +13

4

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant

enthalten in: Breast cancer research | 2021

von Jacquemetton, J. | Kassem, L. | Poulard, C. | +13

5

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance

enthalten in: Nature communications | 2020

von Montaudon, E. | Nikitorowicz-Buniak, J. | Sourd, L. | +35

6

Analysis of genomic and non-genomic signalling of oestrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor Alpelisib (BYL719) and fulvestrant

enthalten in: ResearchSquare.com | 2020

von Romancer, M. | Jacquemetton, J. | Kassem, L. | +13

7

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities

enthalten in: Oncogene | 2020

von Pancholi, S. | Ribas, R. | Simigdala, N. | +16

8

Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer

enthalten in: Oncogene | 2020

von Simões, B. | Santiago-Gómez, A. | Chiodo, C. | +16

9

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

enthalten in: Science translational medicine | 2020

von Coussy, F. | El-Botty, R. | Château-Joubert, S. | +31

10

A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer

enthalten in: International journal of cancer | 2019

von Coussy, F. | de Koning, L. | Lavigne, M. | +27